Experimental myositis inducible with transfer of dendritic cells presenting a skeletal muscle C protein-derived CD8 epitope peptide

International Immunology

Volumn 27, Issue 7, 2015, Pages 327-332

  Okiyama, Naoko ^a,b,c,d,e   Hasegawa, Hisanori ^a   Oida, Takatoku ^c   Hirata, Shinya ^a   Yokozeki, Hiroo ^b   Fujimoto, Manabu ^e   Miyasaka, Nobuyuki ^a,b   Kohsaka, Hitoshi ^a,b,d  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^b TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^c JAPAN SOCIETY FOR THE PROMOTION OF SCIENCE   (Japan)

^d Institute of Physical and Chemical Research   (Japan)

^e UNIVERSITY OF TSUKUBA   (Japan)

Author keywords

Bone marrow derived dendritic cell; CD4 T cell; RMA S cell

Indexed keywords

AMINO ACID; CD4 ANTIGEN; CD8 ANTIGEN; EPITOPE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MONOCLONAL ANTIBODY; MUSCLE PROTEIN; PEPTIDE; PEPTIDE FRAGMENT; SKELETAL MUSCLE C PROTEIN; UNCLASSIFIED DRUG; C REACTIVE PROTEIN;

AMINO ACID SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BONE MARROW DERIVED DENDRITIC CELL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL ASSAY; CONTROLLED STUDY; EXPERIMENTAL MYOSITIS; FEMALE; IMMUNOHISTOCHEMISTRY; INTERNET; LYMPHOMA CELL LINE; MOUSE; MYOSITIS; NONHUMAN; POLYMYOSITIS; PRIORITY JOURNAL; PROTEIN BINDING; SKELETAL MUSCLE; ANIMAL; C57BL MOUSE; CHEMISTRY; DENDRITIC CELL; DISEASE MODEL; IMMUNOLOGY; PATHOLOGY; TRANSPLANTATION;

ANIMALS; C-REACTIVE PROTEIN; CD8-POSITIVE T-LYMPHOCYTES; DENDRITIC CELLS; DISEASE MODELS, ANIMAL; EPITOPES, T-LYMPHOCYTE; FEMALE; MICE; MICE, INBRED C57BL; MUSCLE, SKELETAL; MYOSITIS; PEPTIDES;

EID: 84936743078     PISSN: 09538178     EISSN: 14602377     Source Type: Journal    
DOI: 10.1093/intimm/dxv001     Document Type: Article

References (39)

1. Dalakas, M. C. and Hohlfeld, R. 2003. Polymyositis and dermatomyositis. Lancet 362:971.
2. Arahata, K. and Engel, A. G. 1984. Monoclonal antibody analysis of mononuclear cells in myopathies. I: quantitation of subsets according to diagnosis and sites of accumulation and demonstration and counts of muscle fibers invaded by T cells. Ann. Neurol. 16:193.
3. Engel, A. G. and Arahata, K. 1984. Monoclonal antibody analysis of mononuclear cells in myopathies. II: phenotypes of autoinvasive cells in polymyositis and inclusion body myositis. Ann. Neurol. 16:209.
4. Engel, A. G., Arahata, K. and Emslie-Smith, A. 1990. Immune effector mechanisms in inflammatory myopathies. Res. Publ. Assoc. Res. Nerv. Ment. Dis. 68:141.
5. Goebels, N., Michaelis, D., Engelhardt, M. et al. 1996. Differential expression of perforin in muscle-infiltrating T cells in polymyositis and dermatomyositis. J. Clin. Invest. 97:2905.
6. Sugihara, T., Sekine, C., Nakae, T. et al. 2007. A new murine model to define the critical pathologic and therapeutic mediators of polymyositis. Arthritis Rheum. 56:1304.
7. Kojima, T., Tanuma, N., Aikawa, Y., Shin, T., Sasaki, A. and Matsumoto, Y. 1997. Myosin-induced autoimmune polymyositis in the rat. J. Neurol. Sci. 151:141.
8. Kohyama, K. and Matsumoto, Y. 1999. C-protein in the skeletal muscle induces severe autoimmune polymyositis in Lewis rats. J. Neuroimmunol. 98:130.
9. Okiyama, N., Sugihara, T., Iwakura, Y., Yokozeki, H., Miyasaka, N. and Kohsaka, H. 2009. Therapeutic effects of interleukin-6 blockade in a murine model of polymyositis that does not require interleukin-17A. Arthritis Rheum. 60:2505.
10. Sugihara, T., Okiyama, N., Suzuki, M. et al. 2010. Definitive engagement of cytotoxic CD8 T cells in C protein-induced myositis, a murine model of polymyositis. Arthritis Rheum. 62:3088.
11. Rammensee, H. G., Friede, T. and Stevanoviíc, S. 1995. MHC ligands and peptide motifs: first listing. Immunogenetics 41:178.
12. Rammensee, H., Bachmann, J., Emmerich, N. P., Bachor, O. A. and Stevanovic, S. 1999. SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics 50:213.
13. Parker, K. C., Shields, M., DiBrino, M., Brooks, A. and Coligan, J. E. 1995. Peptide binding to MHC class I molecules: implications for antigenic peptide prediction. Immunol. Res. 14:34.
14. Nielsen, M., Lundegaard, C., Worning, P. et al. 2003. Reliable prediction of T-cell epitopes using neural networks with novel sequence representations. Protein Sci. 12:1007.
15. Lundegaard, C., Lamberth, K., Harndahl, M., Buus, S., Lund, O. and Nielsen, M. 2008. NetMHC-3.0: accurate web accessible predictions of human, mouse and monkey MHC class I affinities for peptides of length 8-11. Nucleic Acids Res. 36:W509.
16. Townsend, A., Ohlén, C., Bastin, J., Ljunggren, H. G., Foster, L. and Kärre, K. 2007. Pillars article: association of class I major histocompatibility heavy and light chains induced by viral peptides. Nature 1989. 340: 443-448. J. Immunol. 179:4301.
17. Lutz, M. B., Kukutsch, N., Ogilvie, A. L. et al. 1999. An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow. J. Immunol. Methods 223:77.
18. Titus, R. G., Ceredig, R., Cerottini, J. C. and Louis, J. A. 1985. Therapeutic effect of anti-L3T4 monoclonal antibody GK1.5 on cutaneous leishmaniasis in genetically-susceptible BALB/c mice. J. Immunol. 135:2108.
19. Mogi, S., Sakurai, J., Kohsaka, T. et al. 2000. Tumour rejection by gene transfer of 4-1BB ligand into a CD80(+) murine squamous cell carcinoma and the requirements of co-stimulatory molecules on tumour and host cells. Immunology 101:541.
20. Galea, I., Stasakova, J., Dunscombe, M. S., Ottensmeier, C. H., Elliott, T. and Thirdborough, S. M. 2012. CD8+ T-cell crosscompetition is governed by peptide-MHC class I stability. Eur. J. Immunol. 42:256.
21. Bennett, S. R., Carbone, F. R., Karamalis, F., Flavell, R. A., Miller, J. F. and Heath, W. R. 1998. Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature 393:478.
22. Ridge, J. P., Di Rosa, F. and Matzinger, P. 1998. A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell. Nature 393:474.
23. Schoenberger, S. P., Toes, R. E., van der Voort, E. I., Offringa, R. and Melief, C. J. 1998. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature 393:480.
24. Ahonen, C. L., Doxsee, C. L., McGurran, S. M. et al. 2004. Combined TLR and CD40 triggering induces potent CD8+ T cell expansion with variable dependence on type I IFN. J. Exp. Med. 199:775.
25. Llopiz, D., Dotor, J., Zabaleta, A. et al. 2008. Combined immunization with adjuvant molecules poly(I:C) and anti-CD40 plus a tumor antigen has potent prophylactic and therapeutic antitumor effects. Cancer Immunol. Immunother. 57:19.
26. Kawachi, I., Tanaka, K., Tanaka, M. and Tsuji, S. 2001. Dendritic cells presenting pyruvate kinase M1/M2 isozyme peptide can induce experimental allergic myositis in BALB/c mice. J. Neuroimmunol. 117:108.
27. Behrens, G., Li, M., Smith, C. M. et al. 2004. Helper T cells, dendritic cells and CTL Immunity. Immunol. Cell Biol. 82:84.
28. Okiyama, N., Sugihara, T., Oida, T. et al. 2012. T lymphocytes and muscle condition act like seeds and soil in a murine polymyositis model. Arthritis Rheum. 64:3741.
29. Tsutsumi, H., Tani, K., Fujii, H. and Miwa, S. 1988. Expression of L-and M-type pyruvate kinase in human tissues. Genomics 2:86.
30. Nagaraju, K., Raben, N., Loeffler, L. et al. 2000. Conditional upregulation of MHC class I in skeletal muscle leads to self-sustaining autoimmune myositis and myositis-specific autoantibodies. Proc. Natl Acad. Sci. USA 97:9209.
31. Gaur, A., Wiers, B., Liu, A., Rothbard, J. and Fathman, C. G. 1992. Amelioration of autoimmune encephalomyelitis by myelin basic protein synthetic peptide-induced anergy. Science 258:1491.
32. Critchfield, J. M., Racke, M. K., Zuniga-Pflucker, J. C. et al. 1994. T cell deletion in high antigen dose therapy of autoimmune encephalomyelitis. Science 263:1139.
33. Tisch, R., Wang, B. and Serreze, D. V. 1999. Induction of glutamic acid decarboxylase 65-specific Th2 cells and suppression of autoimmune diabetes at late stages of disease is epitope dependent. J. Immunol. 163:1178.
34. Bercovici, N., Heurtier, A., Vizler, C. et al. 2000. Systemic administration of agonist peptide blocks the progression of spontaneous CD8-mediated autoimmune diabetes in transgenic mice without bystander damage. J. Immunol. 165:202.
35. Gutermuth, J., Nograles, K. E., Miyagawa, F., Nelson, E., Cho, Y. H. and Katz, S. I. 2009. Self-peptides prolong survival in murine autoimmunity via reduced IL-2/IL-7-mediated STAT5 signaling, CD8 coreceptor, and V alpha 2 down-regulation. J. Immunol. 183:3130.
36. Paek, S. Y., Miyagawa, F., Zhang, H. et al. 2012. Soluble peptide treatment reverses CD8 T-cell-induced disease in a mouse model of spontaneous tissue-selective autoimmunity. J. Invest. Dermatol. 132:677.
37. Aichele, P., Kyburz, D., Ohashi, P. S. et al. 1994. Peptide-induced T-cell tolerance to prevent autoimmune diabetes in a transgenic mouse model. Proc. Natl Acad. Sci. USA 91:444.
38. von Herrath, M. G., Coon, B., Lewicki, H., Mazarguil, H., Gairin, J. E. and Oldstone, M. B. 1998. In vivo treatment with a MHC class I-restricted blocking peptide can prevent virus-induced autoimmune diabetes. J. Immunol. 161:5087.
39. Sugihara, T., Okiyama, N., Watanabe, N., Miyasaka, N. and Kohsaka, H. 2012. Interleukin-1 and tumor necrosis factor a blockade treatment of experimental polymyositis in mice. Arthritis Rheum. 64:2655.